Differential effects of carvedilol and metoprolol on renal function in patients with heart failure

Hiroyuki Ito, Yuji Nagatomo, Takashi Kohno, Toshihisa Anzai, Tomomi Meguro, Satoshi Ogawa, Tsutomu Yoshikawa

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: The aim of the present study was to verify the effects of /S-blockers on renal function in patients with heart failure (HF).&Methods and Results: A total of 40 patients with HF (New York Heart Association class, II-III) were enrolled, who had S-blocker therapy initiated with carvedilol (n=23) or metoprolol (n=17). The changes in renal and cardiac function were retrospectively analyzed over 16 weeks. The study population was divided into 2 groups according to the median baseline (65.9ml/min) of estimated glomerular fltration rate (eGFR) calculated by the Modifcation of Diet in Renal Disease formula. eGFR signifcantly decreased in the higher eGFR group (P=0.04), but did not in the lower eGFR group. Left ventricular ejection fraction signifcantly increased in both groups with lower eGFR (P=0.01) and higher eGFR (P<0.01). There was an interaction between plasma norepinephrine concentration and eGFR in terms of β-blocker treatment (P=0.02, ANOVA). eGFR signifcantly decreased in patients who received metoprolol (from 75.7±33.5 to 59.5±20.0ml·min- 1·1.73 m -2, P<0.01), but did not change in those who received carvedilol (from 67.1±27.7ml·min- 1·1.73 m -2 to 65.6±23.2ml·min- 1·1.73m -2).&Conclusions: β -Blockers preserved renal function in HF patients with lower baseline eGFR, but not in those with higher baseline eGFR. Carvedilol may be preferable to metoprolol to prevent the development of chronic kidney disease during β-blocker therapy for HF.

Original languageEnglish
Pages (from-to)1578-1583
Number of pages6
JournalCirculation Journal
Volume74
Issue number8
DOIs
Publication statusPublished - 2010

Fingerprint

Metoprolol
Heart Failure
Kidney
Chronic Renal Insufficiency
Stroke Volume
Norepinephrine
Analysis of Variance
Therapeutics
Diet
carvedilol
Population

Keywords

  • β-blocker
  • Carvedilol
  • Glomerular filtration rate
  • Heart failure
  • Metoprolol

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Ito, H., Nagatomo, Y., Kohno, T., Anzai, T., Meguro, T., Ogawa, S., & Yoshikawa, T. (2010). Differential effects of carvedilol and metoprolol on renal function in patients with heart failure. Circulation Journal, 74(8), 1578-1583. https://doi.org/10.1253/circj.CJ-09-0865

Differential effects of carvedilol and metoprolol on renal function in patients with heart failure. / Ito, Hiroyuki; Nagatomo, Yuji; Kohno, Takashi; Anzai, Toshihisa; Meguro, Tomomi; Ogawa, Satoshi; Yoshikawa, Tsutomu.

In: Circulation Journal, Vol. 74, No. 8, 2010, p. 1578-1583.

Research output: Contribution to journalArticle

Ito, H, Nagatomo, Y, Kohno, T, Anzai, T, Meguro, T, Ogawa, S & Yoshikawa, T 2010, 'Differential effects of carvedilol and metoprolol on renal function in patients with heart failure', Circulation Journal, vol. 74, no. 8, pp. 1578-1583. https://doi.org/10.1253/circj.CJ-09-0865
Ito, Hiroyuki ; Nagatomo, Yuji ; Kohno, Takashi ; Anzai, Toshihisa ; Meguro, Tomomi ; Ogawa, Satoshi ; Yoshikawa, Tsutomu. / Differential effects of carvedilol and metoprolol on renal function in patients with heart failure. In: Circulation Journal. 2010 ; Vol. 74, No. 8. pp. 1578-1583.
@article{6dfc62fe74a140c0afa2d2683d8d73f1,
title = "Differential effects of carvedilol and metoprolol on renal function in patients with heart failure",
abstract = "Background: The aim of the present study was to verify the effects of /S-blockers on renal function in patients with heart failure (HF).&Methods and Results: A total of 40 patients with HF (New York Heart Association class, II-III) were enrolled, who had S-blocker therapy initiated with carvedilol (n=23) or metoprolol (n=17). The changes in renal and cardiac function were retrospectively analyzed over 16 weeks. The study population was divided into 2 groups according to the median baseline (65.9ml/min) of estimated glomerular fltration rate (eGFR) calculated by the Modifcation of Diet in Renal Disease formula. eGFR signifcantly decreased in the higher eGFR group (P=0.04), but did not in the lower eGFR group. Left ventricular ejection fraction signifcantly increased in both groups with lower eGFR (P=0.01) and higher eGFR (P<0.01). There was an interaction between plasma norepinephrine concentration and eGFR in terms of β-blocker treatment (P=0.02, ANOVA). eGFR signifcantly decreased in patients who received metoprolol (from 75.7±33.5 to 59.5±20.0ml·min- 1·1.73 m -2, P<0.01), but did not change in those who received carvedilol (from 67.1±27.7ml·min- 1·1.73 m -2 to 65.6±23.2ml·min- 1·1.73m -2).&Conclusions: β -Blockers preserved renal function in HF patients with lower baseline eGFR, but not in those with higher baseline eGFR. Carvedilol may be preferable to metoprolol to prevent the development of chronic kidney disease during β-blocker therapy for HF.",
keywords = "β-blocker, Carvedilol, Glomerular filtration rate, Heart failure, Metoprolol",
author = "Hiroyuki Ito and Yuji Nagatomo and Takashi Kohno and Toshihisa Anzai and Tomomi Meguro and Satoshi Ogawa and Tsutomu Yoshikawa",
year = "2010",
doi = "10.1253/circj.CJ-09-0865",
language = "English",
volume = "74",
pages = "1578--1583",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "8",

}

TY - JOUR

T1 - Differential effects of carvedilol and metoprolol on renal function in patients with heart failure

AU - Ito, Hiroyuki

AU - Nagatomo, Yuji

AU - Kohno, Takashi

AU - Anzai, Toshihisa

AU - Meguro, Tomomi

AU - Ogawa, Satoshi

AU - Yoshikawa, Tsutomu

PY - 2010

Y1 - 2010

N2 - Background: The aim of the present study was to verify the effects of /S-blockers on renal function in patients with heart failure (HF).&Methods and Results: A total of 40 patients with HF (New York Heart Association class, II-III) were enrolled, who had S-blocker therapy initiated with carvedilol (n=23) or metoprolol (n=17). The changes in renal and cardiac function were retrospectively analyzed over 16 weeks. The study population was divided into 2 groups according to the median baseline (65.9ml/min) of estimated glomerular fltration rate (eGFR) calculated by the Modifcation of Diet in Renal Disease formula. eGFR signifcantly decreased in the higher eGFR group (P=0.04), but did not in the lower eGFR group. Left ventricular ejection fraction signifcantly increased in both groups with lower eGFR (P=0.01) and higher eGFR (P<0.01). There was an interaction between plasma norepinephrine concentration and eGFR in terms of β-blocker treatment (P=0.02, ANOVA). eGFR signifcantly decreased in patients who received metoprolol (from 75.7±33.5 to 59.5±20.0ml·min- 1·1.73 m -2, P<0.01), but did not change in those who received carvedilol (from 67.1±27.7ml·min- 1·1.73 m -2 to 65.6±23.2ml·min- 1·1.73m -2).&Conclusions: β -Blockers preserved renal function in HF patients with lower baseline eGFR, but not in those with higher baseline eGFR. Carvedilol may be preferable to metoprolol to prevent the development of chronic kidney disease during β-blocker therapy for HF.

AB - Background: The aim of the present study was to verify the effects of /S-blockers on renal function in patients with heart failure (HF).&Methods and Results: A total of 40 patients with HF (New York Heart Association class, II-III) were enrolled, who had S-blocker therapy initiated with carvedilol (n=23) or metoprolol (n=17). The changes in renal and cardiac function were retrospectively analyzed over 16 weeks. The study population was divided into 2 groups according to the median baseline (65.9ml/min) of estimated glomerular fltration rate (eGFR) calculated by the Modifcation of Diet in Renal Disease formula. eGFR signifcantly decreased in the higher eGFR group (P=0.04), but did not in the lower eGFR group. Left ventricular ejection fraction signifcantly increased in both groups with lower eGFR (P=0.01) and higher eGFR (P<0.01). There was an interaction between plasma norepinephrine concentration and eGFR in terms of β-blocker treatment (P=0.02, ANOVA). eGFR signifcantly decreased in patients who received metoprolol (from 75.7±33.5 to 59.5±20.0ml·min- 1·1.73 m -2, P<0.01), but did not change in those who received carvedilol (from 67.1±27.7ml·min- 1·1.73 m -2 to 65.6±23.2ml·min- 1·1.73m -2).&Conclusions: β -Blockers preserved renal function in HF patients with lower baseline eGFR, but not in those with higher baseline eGFR. Carvedilol may be preferable to metoprolol to prevent the development of chronic kidney disease during β-blocker therapy for HF.

KW - β-blocker

KW - Carvedilol

KW - Glomerular filtration rate

KW - Heart failure

KW - Metoprolol

UR - http://www.scopus.com/inward/record.url?scp=77955081311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955081311&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-09-0865

DO - 10.1253/circj.CJ-09-0865

M3 - Article

VL - 74

SP - 1578

EP - 1583

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 8

ER -